Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00082966 | Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00512980 | PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma | terminated | Phase 2 | — | University of CologneOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT01164345 |
| Mozobil for Autologous Stem Cell Mobilization |
| completed |
| Phase 2 |
| 20 |
| Sheba Medical CenterOTHER_GOV |
| 1 |
| Dec 3, 2015 |
| clinicaltrials |
| NCT01050946 | Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit(Haplo/Cord) | terminated | Phase 2 | 1 | Medical College of WisconsinOTHER | 0 | Nov 20, 2015 | clinicaltrials |
| NCT01187303 | Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) | completed | Phase 2 | 28 | University of CologneOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT00795613 | Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)(HD0607) | unknown | Phase 2 | 450 | Ospedale Santa Croce-Carle CuneoOTHER | 2 | Oct 19, 2015 | clinicaltrials |
| NCT00284804 | A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease | completed | Phase 2 | 74 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 12, 2015 | clinicaltrials |
| NCT01412307 | A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma(LEBEN) | unknown | Phase 1 / Phase 2 | 36 | Istituto Nazionale Tumori IRCCS - Fondazione G. PascaleNETWORK | 1 | Aug 11, 2015 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT00358982 | Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma | terminated | Phase 2 | 51 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 3, 2015 | clinicaltrials |
| NCT00543582 | MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma | terminated | Phase 2 | 23 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jul 1, 2015 | clinicaltrials |
| NCT00003210 | Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease | completed | Phase 2 | 105 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00337194 | SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00916045 | Pilot Study of Unrelated Cord Blood Transplantation | terminated | Phase 2 | 40 | King's College Hospital NHS TrustOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT02275598 | Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma | unknown | Phase 2 | 12 | University of Modena and Reggio EmiliaOTHER | 1 | Oct 27, 2014 | clinicaltrials |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00225173 | Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease | terminated | Phase 2 | 45 | Stanford UniversityOTHER | 1 | Aug 27, 2014 | clinicaltrials |
| NCT01283776 | Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation(OCTET-CY) | completed | Phase 2 | 11 | University of CologneOTHER | 1 | Jun 10, 2014 | clinicaltrials |
| NCT00597714 | Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | completed | Phase 2 | 264 | David Rizzieri, MDOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00117988 | 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00132028 | Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00392314 | Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision. | completed | Phase 2 | 365 | Rambam Health Care CampusOTHER | 1 | May 9, 2014 | clinicaltrials |
| NCT00901225 | Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant | completed | Phase 2 | 21 | Duke UniversityOTHER | 1 | May 7, 2014 | clinicaltrials |
| NCT00724984 | Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma(PCYC-0403) | completed | Phase 1 / Phase 2 | 55 | Pharmacyclics LLC.INDUSTRY | 1 | Apr 7, 2014 | clinicaltrials |
| NCT02007811 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination(B-cell therapy) | unknown | Phase 1 / Phase 2 | 15 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 26, 2014 | clinicaltrials |
| NCT00396201 | AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease | completed | Phase 2 | 22 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00444912 | The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) | completed | Phase 2 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00665314 | Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). | completed | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 11, 2014 | clinicaltrials |
| NCT01884441 | Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients | unknown | Phase 2 | 59 | Armando Santoro, MDOTHER | 1 | Jan 29, 2014 | clinicaltrials |
| NCT01037478 | Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma(SAPHIRE) | completed | Phase 2 | 37 | 4SC AGINDUSTRY | 3 | Jan 16, 2014 | clinicaltrials |
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | terminated | Phase 2 | 1 | Texas Oncology Cancer CenterINDUSTRY | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01983761 | Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation | unknown | Phase 1 / Phase 2 | 25 | Targazyme, Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT00393380 | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor | terminated | Phase 2 | 13 | The Emmes Company, LLCINDUSTRY | 1 | Apr 29, 2013 | clinicaltrials |
| NCT01333605 | IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma | unknown | Phase 2 | 43 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT00086840 | CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00359892 | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma | completed | Phase 2 | 13 | Gemin XINDUSTRY | 1 | Aug 6, 2012 | clinicaltrials |
| NCT01014507 | Protection of Ovarian Function in Female Patients With Hodgkin Lymphoma(PROFE) | completed | Phase 2 | 60 | University of CologneOTHER | 0 | Jun 25, 2012 | clinicaltrials |
| NCT01263899 | A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies | completed | Phase 2 | 28 | S*BIOINDUSTRY | 2 | Apr 20, 2012 | clinicaltrials |
| NCT00144677 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00144703 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation | completed | Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00051597 | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies | completed | Phase 1 / Phase 2 | 70 | Seagen Inc.INDUSTRY | 1 | Oct 12, 2011 | clinicaltrials |
| NCT00797472 | Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease | unknown | Phase 2 | 120 | American Scitech InternationalOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00283439 | A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | completed | Phase 1 / Phase 2 | 39 | AmgenINDUSTRY | 0 | Jun 20, 2011 | clinicaltrials |
| NCT01300156 | Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL) | unknown | Phase 2 | 37 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 21, 2011 | clinicaltrials |
| NCT00179816 | Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors | unknown | Phase 1 / Phase 2 | 12 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Oct 11, 2010 | clinicaltrials |
| NCT00636311 | A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma | completed | Phase 2 | 13 | Istituto Clinico HumanitasOTHER | 1 | Sep 2, 2010 | clinicaltrials |
| NCT00232440 | Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma | completed | Phase 1 / Phase 2 | 20 | University Health Network, TorontoOTHER | 1 | Aug 11, 2010 | clinicaltrials |
| NCT01177371 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2010 | clinicaltrials |
| NCT00275262 | A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation | terminated | Phase 2 | 25 | AbbottINDUSTRY | 1 | May 6, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Dec 4, 2015source: clinicaltrials